---
document_datetime: 2025-12-21 09:04:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/synagis.html
document_name: synagis.html
version: success
processing_time: 0.1188035
conversion_datetime: 2025-12-25 05:23:15.44379
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Synagis

[RSS](/en/individual-human-medicine.xml/66784)

##### Authorised

This medicine is authorised for use in the European Union

palivizumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Synagis](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Synagis. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Synagis.

Expand section

Collapse section

## What is Synagis?

Synagis is a powder and solvent that are made up into a solution for injection. It contains the active substance palivizumab.

## What is Synagis used for?

Synagis is used to prevent serious lower respiratory tract (lung) disease caused by respiratory syncytial virus (RSV) that would require hospitalisation. It is used in the following groups of children, who are at high risk for this disease:

- children who are less than six months old and were born five or more weeks prematurely (at 35 weeks gestation or less);
- children who are less than two years of age and have had treatment for bronchopulmonary dysplasia (abnormal lung tissue, usually seen in babies born prematurely) within the last six months;
- children who are less than two years of age and were born with a serious heart disease.

The medicine can only be obtained with a prescription.

## How is Synagis used?

Synagis is given once a month when there is a risk of RSV infection in the community: in the northern hemisphere, this is from November to April. If possible, the first dose should be given before this season starts. Patients generally receive a total of five monthly injections into the thigh muscle.

## How does Synagis work?

The active substance in Synagis, palivizumab, is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen). Palivizumab has been designed to attach to a protein called 'fusion protein A' on the surface of RSV. When palivizumab is attached to this protein, the virus becomes unable to enter the body's cells, especially those in the lungs. This helps to prevent RSV infection.

## How has Synagis been studied?

The main study of Synagis was carried out in 1,502 high-risk children and compared Synagis with placebo (a dummy treatment) during one RSV season. Another study was also carried out comparing Synagis with placebo in 1,287 children who were born with heart disease. In both studies, the main measure of effectiveness was the number of children who had to be admitted to hospital because of RSV infection.The effects of Synagis were first tested in experimental models before being studied in humans.

## What benefit has Synagis shown during the studies?

Synagis was more effective than placebo in reducing RSV-related hospitalisations: 5% of the children who received Synagis were admitted to hospital for RSV infection during the study, compared with 11% of those who received placebo. This was a reduction of 55%. In children born with heart disease, there was a reduction of 45%.

## What is the risk associated with Synagis?

The most common side effects with Synagis (seen in between 1 and 10 patients in 100) are fever and rash. For the full list of all side effects reported with Synagis, see the package leaflet.

Synagis must not be used in people who are hypersensitive (allergic) to palivizumab, any of the other ingredients or other 'humanised' monoclonal antibodies.

## Why has Synagis been approved?

The CHMP decided that Synagis's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Synagis:

The European Commission granted a marketing authorisation valid throughout the European Union for Synagis on 13 August 1999.

For more information about treatment with Synagis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Synagis : EPAR - Summary for the public

English (EN) (93.97 KB - PDF)

**First published:** 11/09/2009

**Last updated:** 18/12/2013

[View](/en/documents/overview/synagis-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-396)

български (BG) (123.31 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/bg/documents/overview/synagis-epar-summary-public_bg.pdf)

español (ES) (94.88 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/es/documents/overview/synagis-epar-summary-public_es.pdf)

čeština (CS) (118.85 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/cs/documents/overview/synagis-epar-summary-public_cs.pdf)

dansk (DA) (93.47 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/da/documents/overview/synagis-epar-summary-public_da.pdf)

Deutsch (DE) (73.35 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/de/documents/overview/synagis-epar-summary-public_de.pdf)

eesti keel (ET) (72.87 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/et/documents/overview/synagis-epar-summary-public_et.pdf)

ελληνικά (EL) (124.89 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/el/documents/overview/synagis-epar-summary-public_el.pdf)

français (FR) (97.13 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/fr/documents/overview/synagis-epar-summary-public_fr.pdf)

hrvatski (HR) (109.21 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/hr/documents/overview/synagis-epar-summary-public_hr.pdf)

italiano (IT) (93.58 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/it/documents/overview/synagis-epar-summary-public_it.pdf)

latviešu valoda (LV) (93.64 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/lv/documents/overview/synagis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (118.23 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/lt/documents/overview/synagis-epar-summary-public_lt.pdf)

magyar (HU) (94.32 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/hu/documents/overview/synagis-epar-summary-public_hu.pdf)

Malti (MT) (99.53 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/mt/documents/overview/synagis-epar-summary-public_mt.pdf)

Nederlands (NL) (74.57 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/nl/documents/overview/synagis-epar-summary-public_nl.pdf)

polski (PL) (98.72 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/pl/documents/overview/synagis-epar-summary-public_pl.pdf)

português (PT) (95.02 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/pt/documents/overview/synagis-epar-summary-public_pt.pdf)

română (RO) (118.03 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/ro/documents/overview/synagis-epar-summary-public_ro.pdf)

slovenčina (SK) (119.32 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/sk/documents/overview/synagis-epar-summary-public_sk.pdf)

slovenščina (SL) (112.46 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/sl/documents/overview/synagis-epar-summary-public_sl.pdf)

Suomi (FI) (93.95 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/fi/documents/overview/synagis-epar-summary-public_fi.pdf)

svenska (SV) (94.12 KB - PDF)

**First published:**

11/09/2009

**Last updated:**

18/12/2013

[View](/sv/documents/overview/synagis-epar-summary-public_sv.pdf)

Synagis : EPAR - Risk Management Plan

English (EN) (10.91 MB - PDF)

**First published:** 22/03/2023

**Last updated:** 12/12/2025

[View](/en/documents/rmp-summary/synagis-epar-risk-management-plan_en.pdf)

## Product information

Synagis : EPAR - Product Information

English (EN) (172.93 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 11/10/2023

[View](/en/documents/product-information/synagis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-920)

български (BG) (216.08 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/bg/documents/product-information/synagis-epar-product-information_bg.pdf)

español (ES) (194.05 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/es/documents/product-information/synagis-epar-product-information_es.pdf)

čeština (CS) (189.81 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/cs/documents/product-information/synagis-epar-product-information_cs.pdf)

dansk (DA) (187.82 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/da/documents/product-information/synagis-epar-product-information_da.pdf)

Deutsch (DE) (237.53 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/de/documents/product-information/synagis-epar-product-information_de.pdf)

eesti keel (ET) (181.42 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/et/documents/product-information/synagis-epar-product-information_et.pdf)

ελληνικά (EL) (217.24 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/el/documents/product-information/synagis-epar-product-information_el.pdf)

français (FR) (208.05 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/fr/documents/product-information/synagis-epar-product-information_fr.pdf)

hrvatski (HR) (195.83 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/hr/documents/product-information/synagis-epar-product-information_hr.pdf)

íslenska (IS) (183.93 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/is/documents/product-information/synagis-epar-product-information_is.pdf)

italiano (IT) (197.62 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/it/documents/product-information/synagis-epar-product-information_it.pdf)

latviešu valoda (LV) (205.73 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/lv/documents/product-information/synagis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (190.55 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/lt/documents/product-information/synagis-epar-product-information_lt.pdf)

magyar (HU) (198.14 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/hu/documents/product-information/synagis-epar-product-information_hu.pdf)

Malti (MT) (219.71 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/mt/documents/product-information/synagis-epar-product-information_mt.pdf)

Nederlands (NL) (190.42 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/nl/documents/product-information/synagis-epar-product-information_nl.pdf)

norsk (NO) (186.89 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/no/documents/product-information/synagis-epar-product-information_no.pdf)

polski (PL) (226.33 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/pl/documents/product-information/synagis-epar-product-information_pl.pdf)

português (PT) (207.6 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/pt/documents/product-information/synagis-epar-product-information_pt.pdf)

română (RO) (218.58 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/ro/documents/product-information/synagis-epar-product-information_ro.pdf)

slovenčina (SK) (213.71 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/sk/documents/product-information/synagis-epar-product-information_sk.pdf)

slovenščina (SL) (181.98 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/sl/documents/product-information/synagis-epar-product-information_sl.pdf)

Suomi (FI) (180.94 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/fi/documents/product-information/synagis-epar-product-information_fi.pdf)

svenska (SV) (190.41 KB - PDF)

**First published:**

04/12/2009

**Last updated:**

11/10/2023

[View](/sv/documents/product-information/synagis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0132 14/09/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Synagis : EPAR - All Authorised presentations

English (EN) (28.04 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 13/09/2021

[View](/en/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-685)

български (BG) (31.13 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/bg/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_bg.pdf)

español (ES) (27.3 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/es/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.72 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/cs/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (29.96 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/da/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.57 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/de/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/et/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (29.27 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/el/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_el.pdf)

français (FR) (50.19 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/fr/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.38 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/hr/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (28.19 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/is/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (27.71 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/it/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (28.6 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/lv/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (28.59 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/lt/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.78 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/hu/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.42 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/mt/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.67 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/nl/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (31.5 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/no/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.02 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/pl/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_pl.pdf)

português (PT) (28.8 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/pt/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_pt.pdf)

română (RO) (27.82 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/ro/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (28.82 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/sk/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (27.95 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/sl/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (28.88 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/fi/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (27.15 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

13/09/2021

[View](/sv/documents/all-authorised-presentations/synagis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Synagis Active substance palivizumab International non-proprietary name (INN) or common name palivizumab Therapeutic area (MeSH) Respiratory Syncytial Virus Infections Anatomical therapeutic chemical (ATC) code J06BD01

### Pharmacotherapeutic group

Immune sera and immunoglobulins

### Therapeutic indication

Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:

- children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season;
- children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;
- children less than two years of age and with haemodynamically significant congenital heart disease.

## Authorisation details

EMA product number EMEA/H/C/000257 Marketing authorisation holder

AstraZeneca AB

SE-151 85 Sodertalje

Opinion adopted 19/05/1999 Marketing authorisation issued 13/08/1999 Revision 46

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Synagis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (321.29 KB - PDF)

**First published:** 04/12/2009

**Last updated:** 11/10/2023

[View](/en/documents/procedural-steps-after/synagis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Synagis-H-C-257-P46-0050 : EPAR - Assessment Report

Adopted

Reference Number: EMA/139142/2018

English (EN) (161.41 KB - PDF)

**First published:** 31/05/2018

**Last updated:** 31/05/2018

[View](/en/documents/variation-report/synagis-h-c-257-p46-0050-epar-assessment-report_en.pdf)

Synagis-H-C-257-P46-047 : EPAR - Assessment Report

Adopted

Reference Number: EMA/107943/2017

English (EN) (145.12 KB - PDF)

**First published:** 29/06/2017

**Last updated:** 29/06/2017

[View](/en/documents/variation-report/synagis-h-c-257-p46-047-epar-assessment-report_en.pdf)

Synagis-H-C-257-P46-048 : EPAR - Assessment Report

Adopted

Reference Number: EMA/107944/2017

English (EN) (124 KB - PDF)

**First published:** 29/06/2017

**Last updated:** 29/06/2017

[View](/en/documents/variation-report/synagis-h-c-257-p46-048-epar-assessment-report_en.pdf)

Synagis-H-C-257-P46-049 : EPAR - Assessment Report

Reference Number: EMA/219845/2017

English (EN) (114.73 KB - PDF)

**First published:** 30/05/2017

**Last updated:** 30/05/2017

[View](/en/documents/variation-report/synagis-h-c-257-p46-049-epar-assessment-report_en.pdf)

Synagis-H-C-000257-P46-046 : EPAR - Assessment Report

Adopted

Reference Number: EMA/726248/2016

English (EN) (99.18 KB - PDF)

**First published:** 25/11/2016

**Last updated:** 25/11/2016

[View](/en/documents/variation-report/synagis-h-c-000257-p46-046-epar-assessment-report_en.pdf)

Synagis-H-C-257-P46-044 : EPAR - Assessment Report

Adopted

Reference Number: EMA/187124/2016

English (EN) (133.37 KB - PDF)

**First published:** 23/06/2016

**Last updated:** 23/06/2016

[View](/en/documents/variation-report/synagis-h-c-257-p46-044-epar-assessment-report_en.pdf)

Synagis-H-C-257-P46-0036 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/780068/2013

English (EN) (265.26 KB - PDF)

**First published:** 06/02/2014

**Last updated:** 06/02/2014

[View](/en/documents/variation-report/synagis-h-c-257-p46-0036-epar-assessment-report_en.pdf)

Synagis-H-C-257-P45-0030 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/533490/2012

English (EN) (152.21 KB - PDF)

**First published:** 04/09/2012

**Last updated:** 04/09/2012

[View](/en/documents/variation-report/synagis-h-c-257-p45-0030-epar-assessment-report_en.pdf)

Synagis : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (94.49 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/synagis-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Synagis : EPAR - Scientific Discussion

English (EN) (292.93 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/synagis-epar-scientific-discussion_en.pdf)

Synagis : EPAR - Procedural steps taken before authorisation

English (EN) (89.31 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/synagis-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Synagis

- [EMEA-001309-PIP01-12 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001309-pip01-12)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/12/2025

## Share this page

[Back to top](#main-content)